Granulocyte–macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial
C Meisel, JC Schefold, R Pschowski… - American journal of …, 2009 - atsjournals.org
C Meisel, JC Schefold, R Pschowski, T Baumann, K Hetzger, J Gregor, S Weber-Carstens…
American journal of respiratory and critical care medicine, 2009•atsjournals.orgRationale: Sustained sepsis-associated immunosuppression is associated with uncontrolled
infection, multiple organ dysfunction, and death. Objectives: In the first controlled biomarker-
guided immunostimulatory trial in sepsis, we tested whether granulocyte–macrophage
colony-stimulating factor (GM-CSF) reverses monocyte deactivation, a hallmark of sepsis-
associated immunosuppression (primary endpoint), and improves the immunological and
clinical course of patients with sepsis. Methods: In a prospective, randomized, double-blind …
infection, multiple organ dysfunction, and death. Objectives: In the first controlled biomarker-
guided immunostimulatory trial in sepsis, we tested whether granulocyte–macrophage
colony-stimulating factor (GM-CSF) reverses monocyte deactivation, a hallmark of sepsis-
associated immunosuppression (primary endpoint), and improves the immunological and
clinical course of patients with sepsis. Methods: In a prospective, randomized, double-blind …
Rationale: Sustained sepsis-associated immunosuppression is associated with uncontrolled infection, multiple organ dysfunction, and death.
Objectives: In the first controlled biomarker-guided immunostimulatory trial in sepsis, we tested whether granulocyte–macrophage colony-stimulating factor (GM-CSF) reverses monocyte deactivation, a hallmark of sepsis-associated immunosuppression (primary endpoint), and improves the immunological and clinical course of patients with sepsis.
Methods: In a prospective, randomized, double-blind, placebo-controlled, multicenter trial, 38 patients (19/group) with severe sepsis or septic shock and sepsis-associated immunosuppression (monocytic HLA-DR [mHLA-DR] <8,000 monoclonal antibodies (mAb) per cell for 2 d) were treated with GM-CSF (4 μg/kg/d) or placebo for 8 days. The patients' clinical and immunological course was followed up for 28 days.
Measurements and Main Results: Both groups showed comparable baseline mHLA-DR levels (5,609 ± 3,628 vs. 5,659 ± 3,332 mAb per cell), which significantly increased within 24 hours in the GM-CSF group. After GM-CSF treatment, mHLA-DR was normalized in 19/19 treated patients, whereas this occurred in 3/19 control subjects only (P < 0.001). GM-CSF also restored ex-vivo Toll-like receptor 2/4–induced proinflammatory monocytic cytokine production. In patients receiving GM-CSF, a shorter time of mechanical ventilation (148 ± 103 vs. 207 ± 58 h, P = 0.04), an improved Acute Physiology and Chronic Health Evaluation-II score (P = 0.02), and a shorter length of both intrahospital and intensive care unit stay was observed (59 ± 33 vs. 69 ± 46 and 41 ± 26 vs. 52 ± 39 d, respectively, both not significant). Side effects related to the intervention were not noted.
Conclusions: Biomarker-guided GM-CSF therapy in sepsis is safe and effective for restoring monocytic immunocompetence. Use of GM-CSF may shorten the time of mechanical ventilation and hospital/intensive care unit stay. A multicenter trial powered for the improvement of clinical parameters and mortality as primary endpoints seems indicated.
Clinical trial registered with www.clinicaltrials.gov (NCT00252915).
ATS Journals